Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UnicoCell Biomed CoTPE:6794 -1.01%83 PS Ratio is 157.23 as of Jul. 16, 2026, which is 10% below its 10-year median of 174.10. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.84 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 930 Biotechnology companies, UnicoCell Biomed Co ranks worse than 87.96% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, UnicoCell Biomed Co's share price is NT$78.30.
UnicoCell Biomed Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.50. Hence, UnicoCell Biomed Co's PS Ratio for today is 157.23.
Warning Sign:
UnicoCell Biomed Co Ltd stock PS Ratio (=166.8) is close to 1-year high of 180.12.
The historical rank and industry rank for UnicoCell Biomed Co's PS Ratio or its related term are showing as below:
TPE:6794'
s PS Ratio Range Over the Past 10 Years
Min: 83.29 Med: 174.1 Max: 1120.25
Current: 157.23
During the past 9 years, UnicoCell Biomed Co's highest PS Ratio was 1120.25. The lowest was 83.29. And the median was 174.10.
TPE:6794's PS Ratio is ranked worse than 87.96% of 930
companies
in the Biotechnology industry
Industry Median: 9.655
vs TPE:6794: 157.23
UnicoCell Biomed Co Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of UnicoCell Biomed Co was -11.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 35.30% per year.
During the past 9 years, UnicoCell Biomed Co's highest 3-Year average Revenue per Share Growth Rate was 60.30% per year. The lowest was -14.40% per year. And the median was 0.10% per year.
Back to Basics: PS Ratio
UnicoCell Biomed Co (TPE:6794) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
UnicoCell Biomed Co PS Ratio Related Terms
UnicoCell Biomed Co PS Ratio Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UnicoCell Biomed Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UnicoCell Biomed Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where UnicoCell Biomed Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
UnicoCell Biomed Co's Share Price of today is NT$78.30. UnicoCell Biomed Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.50.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
UnicoCell Biomed Co (TPE:6794) has a PS Ratio of 157.23 as of Jul. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on UnicoCell Biomed Co and its competitors. This is 10% below median its historical median of 174.10. Over the past decade, UnicoCell Biomed Co's PS Ratio has ranged from 83.29 to 1,120.25. According to the industry distribution chart, UnicoCell Biomed Co ranks #818 out of 930 companies in the Biotechnology industry, placing it in the top 88%.
Is UnicoCell Biomed Co's PS Ratio too high?
UnicoCell Biomed Co's current PS Ratio of 157.23 is 10% below median its 10-year median of 174.10. Over the past 10 years, this metric has ranged from a low of 83.29 to a high of 1,120.25. The Biotechnology industry median PS Ratio is 9.66. UnicoCell Biomed Co's value of 157.23 is 1528.5% above this industry median. Based on the distribution chart, UnicoCell Biomed Co ranks #818 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UnicoCell Biomed Co ranks #818 out of 930 companies for PS Ratio. This places UnicoCell Biomed Co in the lower half of its industry. The industry median PS Ratio is 9.66. UnicoCell Biomed Co's value of 157.23 is 1528.5% above this benchmark. Historically, UnicoCell Biomed Co's own PS Ratio has ranged from 83.29 to 1,120.25 over the past decade. While the company's 10-year median is 174.10 vs. the industry median of 9.66, UnicoCell Biomed Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.66, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UnicoCell Biomed Co's current PS Ratio of 157.23 is 1528.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on UnicoCell Biomed Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UnicoCell Biomed Co's current PS Ratio is 157.23, which is 10% below median its own 10-year median of 174.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.84, compared to a current price of NT$78.30 — trading 23.1% below its estimated fair value. The current PS Ratio is 157.23, which is 10% below median its 10-year median of 174.10 and 1528.5% above the Biotechnology industry median of 9.66. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current PS Ratio is 157.23 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$78.30 is trading 23.1% below its estimated GF Value™ of NT$101.84.
GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.
Key valuation signals for TPE:6794:
PS Ratio: 157.23 (10% below median its 10-year median of 174.10)
GF Value™: NT$101.84 vs. price of NT$78.30 (23.1% below fair value)
Industry Position: 1528.5% above the Biotechnology median (#818 of 930)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score
Get the complete analysis for TPE:6794
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
